Rationale: Chronic obstructive pulmonary disease (COPD) is a complex disorder with high mortality worldwide. Studies on the role of candidate genes and their polymorphisms in COPD development have so far produced ambiguous results. Objectives: The aim of this study was to reveal the role of COPD candidate genes using data collected in previous research. Methods: We performed meta-analyses on 20 polymorphisms in 12 genes, after searching the PubMed and Embase databases for publications on COPD. These genes involve three main pathways associated with COPD development: the inflammatory, proteaseantiprotease balance, and antioxidant pathways. Measurements and Main Results: We obtained significant results for three TGFB1 polymorphisms, although these were based only on a few studies. The IL1RN VNTR polymorphism increases the risk for COPD (odds ratio [OR], 1.7; 95% confidence interval [CI], 1.09-2.65), whereas the TNFA 2308 G/A polymorphism does so only in Asian populations (OR, 2.01; 95% CI, 1.21-3.31). The GSTP1 I105V polymorphism was protective for COPD in Asian populations only (OR, 0.69; 95% CI, 0.56-0.85).
Chronic obstructive pulmonary disease (COPD) is a complex disorder characterized by expiratory airway obstruction and lung tissue destruction. In 2002 more than 3 million people died of COPD and, according to the World Health Organization, by 2030 COPD is expected to become the third leading cause of death worldwide (1) . . Smoking is the major risk factor for its development, but genetic susceptibility is believed to play a determining role in the development of the disease because only a relatively small proportion of smokers (10-15%) (2) develops symptomatic COPD and differences in cigarette smoke exposure account for only a small amount of the variation seen in lung function. Family-based and twin studies have shown that lung function is heritable and COPD clusters within families.
A well-known example of a strong genetic factor predictive of the development of COPD is a 1 -antitrypsin (AAT) deficiency carrier status. AAT deficiency is a very strong genetic trait that is related to severe, early-onset COPD. The SERPINA1 gene (coding AAT-serine protease inhibitor, of which the main target is neutrophil elastase) was for many years the only genetic factor known to be associated with COPD development. However, only 1-2% of patients with COPD inherit this AAT deficiency (3); hence other genes are believed to play a role in most COPD cases.
Because only 10 to 15% of smokers develop COPD (2), the concept of the ''genetically susceptible'' smoker has been proposed (i.e., a person who will develop COPD from smoking, whereas others will not). These susceptible smokers show a premature onset of decline in lung function and a more rapid rate of decline later in life compared with nonsusceptible smokers. Smoking induces an inflammatory response and oxidative stress in the airways and lung tissue. This ultimately leads to increased numbers of goblet cells, airway remodeling, and tissue destruction, phenotypes that accompany COPD. It is thus likely that genetic studies on candidate genes have initially focused on these typical COPD pathways induced by smoking, in addition to studying the enzymes that detoxify cigarette smoke products. Repair mechanisms are important as a response to lung tissue injury induced by cigarette smoke, so that genes involved in the protease/antiprotease balance are also considered to be candidate genes for COPD.
The majority of genetic studies on COPD so far have been performed in relatively small samples of different ethnic populations, and resulted in unclear and sometimes contradictory results. Our aim was to summarize the current evidence for strong candidate genes and perform meta-analyses on published data to confirm or refute the genes' importance in COPD. The genes we have studied can be grouped into three categories according to their function: (1) inflammatory genes, (2) genes involved in the protease/antiprotease balance, and (3) antioxidant genes.
AT A GLANCE COMMENTARY Scientific Knowledge on the Subject
For many years only one chronic obstructive pulmonary disease gene was known. Searching for additional genes was based on candidate gene studies, which often were impossible to replicate.
What This Study Adds to the Field
The choice of populations for a meta-analysis study or replication can strongly affect results for COPD candidate genes, as at least some of the associations have opposite directions.
METHODS Search Strategy and Selection Criteria
We performed a literature search in PubMed using ''COPD [MeSH terms] and gene or polymorphism or pathway'' for data to use in metaanalyses. We also searched PubMed and Embase querying for ''COPD [MeSH] or pulmonary emphysema [MeSH] or COPD or chronic obstructive pulmonary disease [All fields] and genotype or allele or polymorphism or SNP or variant,'' using MeSH/EMTREE terms and free text. There were no limitations of any type in our literature searches. Based on the literature found we selected genes and their polymorphisms for which we performed a second literature search, specifically looking for publications investigating their association with COPD. We also manually searched the references of relevant publications. For the meta-analyses we included only publications that described association of a particular polymorphism in a case-control or population-based study with clearly defined COPD with no other accompanying disease. The definition of COPD cases that were included had to follow the ATS/ERS guidelines (4) or the GOLD criteria (5). Reviews and other publications, such as editorials and letters, were excluded (unless containing original data). In the case of publications that reported only allele frequencies, but in which the authors had checked for Hardy-Weinberg equilibrium (HWE), we calculated genotype frequencies and used them for our meta-analyses. We further checked for HWE in control subjects among all publications reporting genotype frequencies found using the ''genetics'' package for R, which uses x 2 test to compare observed and expected genotype distributions. Publications deviating from HWE (P , 0.05) were excluded. Information about the 69 publications included in our meta-analyses can be found in Table E1 in the online supplement.
Meta-analyses
We included only genes and polymorphisms that were described in at least three different studies in our meta-analyses. This led to 12 genes and 20 polymorphisms in the genes; these are described separately below. We investigated the following genes in relation to COPD: TNFA, TGFB1, IL-6, IL-1B, and IL1RN in the inflammatory pathways, MMP9 in the protease/antiprotease pathway, and GSTP1, GSTM1, GSTT1, EPHX1, SOD2, and SOD3 in the oxidative stress pathway.
Meta-analyses were performed using R (www.r-project.org) with the rmeta package. All odds ratios (ORs) for individual studies were calculated using this package from the contingency tables. For each meta-analysis a Woolf test for heterogeneity among publications was performed, and depending on the result, we used a fixed-effect model for nonheterogeneous studies (Mantel-Haenszel method) or a randomeffect model for heterogeneous studies (DerSimonian-Laird method). The model types are indicated in the relevant figures. For all metaanalyses a genetic model was also applied. A dominant model was used for all single nucleotide polymorphisms (SNPs) and a recessive model for null alleles.
RESULTS
We performed a two-stage literature search, as depicted in Figure 1 . We started with a general search for publications on COPD genetics. A total of 694 publications were found and their abstracts were read to determine their relevance. Some 188 publications passed our criteria and were used to select genes and their polymorphisms for a specific literature search. Of the selected genes, 12 had sufficient numbers of studies and we included them into meta-analyses. From a total of 314 publications we selected only those fulfilling our criteria described in the methods section. We determined genotype data from those publications and checked for HWE in control subjects. The whole process was performed independently by two investigators (J.S. and H.M.B.). All discordances were discussed, brought to consensuses and studies were included or excluded unanimously. In the end 69 publications were included in our study.
Inflammatory Genes
Inflammation is a continuous and ongoing process in the lungs of patients with COPD, and it is even more enhanced in severe and very severe cases (6) . Epithelial cells are activated by cigarette smoking and their mediators further activate CD8 1 cells and neutrophils, which play a crucial role in inflammation in COPD (7) . Genes encoding these mediators have been studied for association with COPD.
Tumor necrosis factor-a. Many studies on this group of genes have concerned tumor necrosis factor-a (TNF-a), the key cytokine responsible for systemic inflammation, as it drives the production and secretion of many inflammatory mediators. TNF-a plasma levels are raised in COPD and positively correlate with COPD severity. Thus polymorphisms in TNFA might contribute to COPD susceptibility, and indeed, some studies have shown associations between different TNFA polymorphisms and COPD (8-10), or emphysematous changes in the lungs in COPD cases (11) . However, the majority of the studies found no associations in white (12) (13) (14) (15) (16) (17) or Asian (18) (19) populations. Our literature search identified 21 studies from 20 publications (8, 10, (14) (15) (16) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) (31) (32) , including those recently published in a meta-analysis by Gingo, 32 giving a total number of 3,552 cases and 3,659 control subjects with 1,028 cases and 1,011 control subjects as carriers of the A allele. We found a nonsignificant increase of COPD risk with the 2308 polymorphism known to increase promoter activity (OR, 1.06; 95% CI, 0.95-1.17) (Figure 1 ). After performing stratified analyses for whites and Asians separately, the association remained nonsignificant, and became even weaker in the white populations (OR, 1.02; 95% CI, 0.92-1.14). Remarkably, the association was significant in the Asian populations with an OR of 2.01 (95% CI, 1.21-3.31) (Figure 2) . The study by Huang and colleagues (20) resulted in an outstanding OR when compared with other studies. A sensitivity analysis showed that excluding the Huang study changed the result of this metaanalysis to nonsignificant (OR, 1.42; 95% CI, 0.81-2.5). However, all estimates of the included studies were in the same direction. Two other TNFA polymorphisms have been less well studied, one being a promoter polymorphism, 2238G/A, possibly increasing promoter activity. We included five publications reporting its genotype or allele frequencies (10, 15, 29, 30, 32) in our meta-analysis, which showed an overall increased, yet nonsignificant, risk of COPD (OR, 1.10; 95% CI, 0.87-1.38) (Figure 2 ). The other polymorphism in the TNF-a gene is located in the first intron at position 1489, and its influence on TNF-a expression is not known (33) . We performed a metaanalysis on six studies from five publications (10, 18, 19, 30, 32) and found a nonsignificant increase of COPD risk (OR, 1.10; 95% CI, 0.92-1.33) (Figure 3 ). It thus seems unlikely that TNF-a is associated with COPD susceptibility in whites, although larger studies are needed to elucidate its role in Asians.
Transforming growth factor-b1. Transforming growth factor-b1 (TGF-b1) is secreted by epithelial cells and macrophages and can cause fibrotic changes in lung tissue. A previous linkage analysis showed an association with chromosome 19 and identified that the association was located in the TGFB1 region after including additional short tandem repeat markers (34) . Later studies showed inconsistent results and the majority failed to show significant associations. Our search resulted in seven publications describing associations of different TGFB1 polymorphisms with COPD (34) (35) (36) (37) (38) (39) (40) , four investigating associations in whites and three in Asians. We performed meta-analyses on four TGFB1 polymorphisms ( Figure 4 ). The minor alleles of rs2241712 and rs1982073 were protective for COPD (OR, 0.73; 95% CI, 0.57-0.94 and OR, 0.70; 95% CI, 0.58-0.84, respectively). The third TGFB1 SNP, rs1800469, was also protective for COPD, but less significantly (OR, 0.76; 95% CI, 0.54-1.08). Meta-analysis of the fourth SNP, rs6957, provided a significant increased risk for COPD (OR, 1.48; 95% CI, 1.13-1.93). A summary of the significant results for TGFB1 SNPs regarding their putative function and direction of association is shown in Table 1 . All these results should be considered with caution, due to the low number of appropriate studies available. In summary, there were too few studies reporting frequencies of TGFB1 SNPs in patients who had COPD and healthy control subjects. Hence it is not possible to draw any definitive conclusions as to their causative role in COPD development.
Interleukins. The most frequently studied IL genes are IL10, IL6, and IL1. IL10 has been identified as a good candidate gene because of its antiinflammatory potential and decreased levels in COPD. IL10 polymorphisms were studied in different contexts, but the number of case-control studies for each SNP was too low to perform an informative meta-analysis.
IL6 is a proinflammatory cytokine, hence SNPs in the gene may cause prolonged airway inflammation, which may contribute to COPD susceptibility. Promoter polymorphisms of IL6 have been studied most frequently, as they can lead to altered protein levels. Because of its high levels in patients with stable COPD, IL-6 has been proposed as a marker of systemic inflammation in COPD. Its function as a predictor of COPD progression is not clear, because there are many sources of this cytokine in the human body besides the lungs (41) . We performed a meta-analysis on the 2174G/C polymorphism, including four publications studying white populations (16, 25, 31, 42) ( Figure 5 ) and found no significant association with an OR of 1.15 (95% CI, 0.92-1.43).
Finally, another group of candidate genes, members of the proinflammatory interleukin 1 (IL1) gene family (encoding two agonists, IL-1a and IL-1b, and antagonist receptor IL-1RN), have been studied. We found eight relevant studies (four in whites and four in Asians) from seven publications (18, 19, 22, 25, 31, 43, 44). We included three IL1B polymorphisms into our meta-analyses (i.e., 2511 C/T and 231 T/C, both suspected to alter the transcriptional activity, and 13954 T/C, a silent substitution known to increase IL1b levels). The IL1RN VNTR (variable number of tandem repeats) polymorphism was also studied, always together with IL1B polymorphisms. This is not surprising as the IL1b/IL1RN ratio is known to be crucial in determining the severity of inflammatory responses (45) and the IL1RN*2 allele (two repeats) has been shown to increase production of IL1b (46) . We found a strong association between this polymorphism and risk for COPD in Asian populations (OR, 1.70; 95% CI, 1.09-2.65), as all the publications we could include had studied Asians ( Figure 6 ).
We found no significant associations of SNPs in IL1B with COPD, that is, position 2511 with OR 1.12 (95% CI, 0.74-1.7), position 231 with OR 1.3 (95% CI, 0.99-1.71), and position 13954 with OR 0.82 (95% CI, 0.63-1.07).
Genes Involved in Protease-Antiprotease Balance
Many proteases secreted by key inflammatory cells are involved in remodeling and progressive degradation of lung tissue. One of these is neutrophil elastase, which is released by neutrophils on activation. Macrophages produce matrix metalloproteinases (MMPs) and cathepsins, which lead to elastolysis and emphysema. CD8 1 cells secrete perforins and granzyme B, which, together with TNF-a, cause cytolysis and apoptosis of alveolar epithelial cells also contributing to emphysema (7) . Although there is a broad spectrum of proteases involved in tissue damage in COPD, MMPs have been studied the most extensively, especially MMP9. We included five studies (three in Asians and two in whites) on MMP9 in our meta-analysis (47) (48) (49) (50) (51) . The SNP at position 21562 causing a C-to-T transition, which is known to alter promoter activity (52) , increased the risk for COPD, with an OR of 1.45, but the result was not significant (95% CI, 0.84-2.50) (Figure 7 ). More studies are needed to reveal its role.
MMPs are inhibited by tissue inhibitors of metalloproteinases (TIMP1-TIMP4). TIMP2 polymorphisms have been studied and shown to be associated with COPD (53) . TIMP1 also plays a role in COPD as its serum concentrations are elevated in COPD patients and correlate inversely with the level of FEV 1 (forced expiratory volume in first second), which is a marker of COPD severity. It did not correlate with emphysema scores, suggesting it only plays a role in the development of airway obstruction (54) .
As mentioned, the SERPINA1 gene coding AAT was for many years the only known genetic factor associated with COPD. The SERPINA1 PI*ZZ genotype is known to cause the most severe AAT deficiency. Increased risk was also found for PI*MZ heterozygotes when compared with PI*MM individuals in a meta-analysis of 16 independent studies, although the level of FEV 1 did not differ between these two groups (55) . The S allele is also known to lower AAT levels. With a metaanalysis on SZ and MS carriers, the SZ carriers had an increased risk for COPD compared with normal allele carriers, PI*MM (OR, 3.26; 95% CI, 1.24-8.57). The MS carriers had a significant increased risk for COPD (OR, 1.19; 95% CI, 1.02-1.38), whereas the number of individuals with a PI*SS genotype was not sufficient to perform a meta-analysis (56).
Antioxidant Genes
Because tobacco smoking is the main cause of COPD, genes involved in using reactive oxygen/nitrogen species (ROS/RNS) delivered with cigarette smoke have also been studied. Two of the most studied genes in the antioxidant pathway are microsomal epoxide hydrolase (EPHX1) and glutathione S-transferase (GST) subunits P1, T1, and M1.
Microsomal epoxide hydrolase. Microsomal epoxide hydrolase (EPHX1) is the first line of defense against toxic epoxides provided with cigarette smoke and it has two polymorphisms that alter its function, Y113H and H139R, corresponding to slow and fast enzyme activity, respectively (57) . A recent metaanalysis on EPHX (58) including 1,847 patients and 2,455 control subjects showed a significant increase in COPD risk (OR, 1.59; 95% CI, 1.14-2.21) for the Y113H polymorphism and a nonsignificant reduction in COPD risk (OR, 0.90; 95% CI, 0.65-1.24) for the H139R polymorphism. We included 18 studies (27, 29, 59-74) describing both polymorphisms in our meta- analyses, among them 11 in whites and 8 in Asians. The Y113H polymorphism was not associated with COPD (OR, 1.02; 95% CI, 0.91-1.14), also after stratification, in whites (OR, 1.02; 95% CI, 0.9-1.15) and in Asians (OR, 1.02; 95% CI, 0.76-1.36) (Figure 8 ). H139R provided a weakly protective role in COPD with a borderline significant OR of 0.91 (95% CI, 0.83-1.01) ( Figure 9 ). Stratification for ethnicity confirmed there was no significant association in whites (OR, 0.96; 95% CI, 0.85-1.07) but revealed a significant association in Asians (OR, 0.76; 95% CI, 0.61-0.96). Glutathione S-transferase. We performed meta-analyses on glutathione S-transferase (GST) null alleles GSTM1 and GSTT1 (Figures 10 and 11 ) under a recessive model, including 14 studies from 11 publications (27, 61, 64, 66, 67, 72, 75-79) and one unpublished work (van Diemen and colleagues, personal communication) for GSTM1, with seven of the studies also covering GSTT1. Five of those studies investigated Asian populations and nine investigated white populations. We found homozygotes for the GSTM1 null allele to have an increased risk for COPD (OR, 1.3; 95% CI, 1.07-1.57). Stratified analysis confirmed this effect in white populations (OR, 1.32; 95% CI, 1.04-1.68) but not in Asians (OR, 1.24; 95% CI, 0.85-1.8). For the GSTT1 null allele we found no significant associations in The isoleucine-to-valine substitution polymorphism at position 105 of GSTP1 (I105V) increases both its catalytic activity for substrates and the metabolism of diol epoxides of polycyclic aromatic hydrocarbons (80) . A second polymorphism, which has been less well studied, is located in exon 6 at position 114 and causes an alanine-to-valine substitution, which alters the protein function in the same way as the previous polymorphism. We combined 12 studies (including 1 unpublished, van Diemen and colleagues, personal communication) in our meta-analysis, 6 being conducted in Asians and 6 in whites (27, 64, 67, 71, 75, 78, 79, (81) (82) (83) (84) , which showed a nonsignificant protective effect for the I105V polymorphism (OR, 0.89; 95% CI, 0.73-1.1) (Figure 12 ). However, stratified analysis showed a significant association in Asians (OR, 0.69; 95% CI, 0.56-0.85), but not in whites (OR, 1.14; 95% CI, 0.96-1.35). Superoxide dismutases. Superoxide anion is delivered with cigarette smoke and is also generated in many resident and attracted inflammatory cells, for example in the defense processes against other ROS. The family of superoxide dismutases (SOD) changes this toxic anion into hydrogen peroxide. There are three members in this family: intracellular copper-zinc SOD (CuZnSOD), mitochondrial manganese SOD (MnSOD), and extracellular SOD (ECSOD), also known as SOD1, SOD2, and SOD3, respectively (85) . Despite their important roles, genes of these enzymes have not yet been widely studied for associations with COPD.
We found four studies investigating the Ala16Val SOD2 polymorphism in COPD, three in whites and one in Asians (86) (87) (88) (89) . Meta-analysis showed an increased risk for COPD (OR, 1.07; 95% CI, 0.82-1.4) (Figure 13 ). However, the result was nonsignificant, because the number of publications was low and the largest study (89) , which influenced our meta-analysis the most, showed a nonsignificant result. More data for this polymorphism are required to reveal its role in COPD.
We also found three publications reporting the association of the SOD3 R213G polymorphism with COPD in white populations (86, 89, 90) . Our meta-analysis had an OR of 0.63 (95% CI, 0.25-1.60) (Figure 14) , indicating a possible protective role by the 213G allele, but our result was not significant.
Recently Dahl and colleagues (91) performed a study on two newly identified SNPs in the SOD3 (rs8192287 and rs8192288), which were found to be significantly associated with an increased risk for COPD hospitalization and mortality in the large, population-based Copenhagen City Heart Study. They found a smaller effect in the second large cohort studied, the Copenhagen General Population Study. In both cohorts, associations of these SNPs were found with reduced FEV 1 % predicted and FVC% predicted. More recently, these results were partially confirmed by Siedlinski and colleagues (89) an association of rs8192288 with reduced FVC, which was of borderline significance. They did not replicate the results for FEV 1 , possibly due to the low number of homozygous individuals.
Overlap with Other Diseases
When considering the association between the polymorphisms in the genes and COPD, it appears that COPD shares some of its genetic background with other complex diseases. According to the HuGE database, up to 28 January 2009, 94 genes had been studied for association with COPD and these are involved in 89 pathways. For asthma 427 genes have been studied, which fall into 125 pathways, and 35 of them overlap with pathways involved in COPD. Table 2 shows the number of publications investigating associations for the genes studied in the context of COPD with a selected number of other complex diseases.
What can we infer from this? We can speculate that many diseases have a shared genetic background, but different (combinations of) polymorphisms in the shared genes determine which disease evolves. This has recently become evident for immune-related disorders (92) but might in fact be true for other diseases as well. In addition, the type of disease that evolves from a shared genetic background can be determined by certain environmental factors, at specific windows of exposure.
For example, a cigarette smoker with a 2308A allele in the TNFA gene can develop either COPD or Crohn disease depending on other environmental factors and other polymorphisms. Especially the latter are likely to be important, because complex disorders are determined by polymorphisms in many loci, underlying a specific genetic profile. So far little is known about these profiles, but new techniques, such as next generation sequencing, might well be able to reveal them.
Summary of Results
For this review we performed meta-analyses on 20 polymorphisms in 12 functional candidate genes that had previously been studied in at least three publications for association with COPD. Only five showed significant associations with COPD. Three of these were located in TGFB1, two providing a protective effect of the minor allele (rs2241712 and rs1982073) and one (rs6957) giving an increased risk for COPD (OR, 1.48). These results should be interpreted with caution because the number of studies was low. Two other polymorphisms showing a significant increase in COPD risk were the IL1RN VNTR polymorphism and the GSTM1 null allele (OR, 1.7 and OR, 1.3, respectively). For all other polymorphisms we studied, the overall meta-analyses resulted in nonsignificant associations or 
had borderline significance, for example, IL1B 231 polymorphism (OR, 1.3; 95%,CI, 0.99-1.71) and H139R EPHX1 polymorphism (OR, 0.91; 95% CI, 0.83-1.01). Because ethnicity might influence the outcome of the results, we performed stratified analyses for the six polymorphisms for which we had a sufficiently large number of studies, namely 2308G/A in TNFA, Y113H and H139R in EPHX1, GSTM1 and GSTT1 null alleles, and I105V in GSTP1.
DISCUSSION
The aim of this review was to reveal the roles of particular polymorphisms studied for association with COPD in a casecontrol design or in population-based studies and to summarize their sometimes conflicting results. The published candidate gene studies are all hypothesis-based. We took into account only those candidate genes that had been reported in a sufficient number of studies in relation to a well-defined, specific COPD phenotype. As shown, when critically evaluated in meta-analyses, some promising candidate genes do not seem to hold up at all. For example, consider the result of our meta-analysis on the TNFA 2308G/A polymorphism: we included 21 studies and found a nonsignificant association, whereas after stratifying for ethnicity we did find it to be significant but only in Asians. These results are in contrast with those published by Gingo and colleagues (32) . This can be explained by the fact that all six studies included in our meta-analysis reported nonsignificant associations. Because Gingo and coworkers did not perform analysis stratified by ethnicity, it cannot be ruled out that the association they observed was mostly due to a true association present in Asian populations, but not in white populations.
The result for the TNFA gene in Asian populations is based on five publications studying a total of 283 cases and 385 control subjects, with 43 and 38 carrying the A allele, respectively. This group is very small compared with the white population, in which 3,269 cases and 3,274 control subjects were present, 985 and 973 carrying the minor A allele, respectively. Is the effect really that strong in the Asian population or is there a publication bias? Results may well be biased, because all Asian studies reported an OR greater than 1. The Y113H polymorphism in EPHX was not associated with COPD in the overall analysis, and remained nonsignificant after analyses on whites and Asians separately. For H139R in EPHX, as in our overall analysis, the association was nonsignificant in whites but showed a significant protective effect in Asian populations, which is of interest because the total number of whites included was more than four times that of Asians (2,347 vs. 679 cases and 4,069 vs. 808 control subjects). Stratified analysis for GSTM1 confirmed an increased risk for COPD, but only in whites and, again, this group was much larger than the Asian group. The GSTT1 null allele was not associated with COPD in the overall analysis and this was also true in both white and Asian populations. By this we confirmed the results published by Hu and colleagues (93) on a GSTM1 and GSTT1 meta-analysis. They found significant increase in COPD risk for the GSTM1 null allele in overall (OR, 1.46; 95% CI, 1.16-1.83) and stratified analysis in nonAsians only (OR, 1.57; 95% CI, 1.19-2.07). The GSTP1 I105V polymorphism was found to have a protective role in Asians, even for the relatively small numbers of subjects studied, suggesting its possible strong effect in this population. Interestingly, the same polymorphism seems to have an opposite effect in whites (Figure 12 ). These results show the importance of ethnicity in genetic studies, as some associations were present in one group but absent in another. Clearly, most of the polymorphisms we described were investigated in white populations. Thus combined analyses could yield diminished results or, on the contrary, indicate general associations which are in fact present in only one of the groups. We also showed that more studies are needed for most of the polymorphisms investigated here, especially in Asian populations, before more conclusive answers can be given.
There are several limitations to our study. First, despite carefully selecting the studies, we cannot ensure homogeneity in either the case or control groups. Normally, patients with COPD are or have been smokers, although this was not always an explicit criterion in the studies included in our meta-analyses ( Table E1 ). Control subjects should be matched for age, sex, and, most of all, smoking history. Specifically the smoking habits, a crucial feature in studies on the etiology of COPD, are often not known, for example, if the control groups are blood donors. Even more importantly, lung function measurements were not performed in this group, so individuals with low lung function may have been included. Some of the studies included blood donors as control subjects and this may have affected the outcome of the study strongly; for example it might have led to the discovery of strong associations, which would be observed due to bias in the participants' smoking status.
Second, the number of studies we used for the meta-analyses for each polymorphism is sometimes insufficient to draw reliable conclusions (e.g., on the TGFB1 polymorphisms). In some cases, when only allele frequencies were given, we calculated genotype frequencies based on HWE. This should not, however, influence the outcome of our analyses, as the number of such studies was relatively small, and the calculated genotype frequencies should not deviate from the actual genotype distributions.
We should mention also the importance of HWE. We excluded 19 studies from some of our meta-analyses due to the lack of HWE in control groups. The most affected was the meta-analysis on the Y113H polymorphism (eight studies were excluded). This was because of a well-known problem with the first primer set used for genotyping: neighboring polymorphism caused an overestimation of the minor allele in this polymorphism. Including all these studies resulted in significant outcomes in the overall analysis and in the white populations (data not shown), similar to another recent meta-analysis (58) . Half of the studies we excluded reported that HWE had been checked and that no deviations had been found. In the case of IL1RN, the only two studies investigating the role of its polymorphism in whites were also excluded for the same reason, leaving only Asian populations in the meta-analysis.
There are many single studies describing association of a particular gene with specific (related) phenotypic outcomes, such as ADAM33 (a disintegrin and metalloproteinase 33) that was first shown to be associated with asthma, then with COPD development in the general population (94) , and later was linked to airway hyperresponsiveness in patients with COPD (95) . Such ''loose replications'' are sometimes interpreted as further proof for a role of that specific gene in the broader disease definitions, but functional studies are clearly necessary to pinpoint the exact role of such SNPs in genes.
It is worth mentioning recent findings from hypothesis-free genomewide association (GWA) studies on patients with lung cancer, which found an association with the nicotinic acetylcholine receptor subunit (CHRNA) gene polymorphisms (96) . There is a debate on whether SNPs in that region have a direct effect on lung cancer or merely mediate smoking habits. Amos and colleagues did not find any association of those SNPs with nicotine dependence (97), whereas Thorgeisson and colleagues (98) and Young and colleagues (99) investigated genotype frequencies of the most strongly associated SNP found in GWA studies, rs16969968 (which is in strong linkage disequilibrium with rs1051730), in patients with lung cancer with and without COPD, and in smoking control subjects, to check whether this association could be confounded by COPD. They found an increased frequency of the AA genotype in both groups compared with control subjects, which means that the CHRNA gene polymorphism is associated with COPD and with lung cancer. Despite the interesting results, this study shows how important it is to select cases and control subjects carefully and to avoid possible confounders. The first GWA study on COPD was published recently (100) and identified associations of the same SNPs as in lung cancer, rs8034191 and rs1051730. Similarly, it still remains to be elucidated whether these SNPs are associated with COPD itself or whether this association is mainly seen because of nicotine addiction among patients with COPD, although Pillai and colleagues (100) found no association with pack-years smoked in two cohorts. This might be because pack-years may not be the most appropriate indicator of addiction. To answer these questions, more studies are needed, especially studies with quantified addiction data. Clearly, none of the polymorphisms investigated here appeared in the GWA studies. This can be explained in part by the stringent criteria applied to select SNPs for replication and the relatively small initial cohort. But we cannot rule out that some of these polymorphisms may not be associated with COPD at all.
In summary, we showed that many candidate genes show no association with COPD after combining independent studies. For the majority of the genes more studies will be needed to reveal their role, especially in Asian populations. We show that ethnicity is very important in genetic studies, and therefore should always be taken into account, given that some associations show different directions for different populations.
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